Oramed Pharmaceuticals Files Q3 2024 10-Q

TL;DR

Oramed Pharma filed its 10-Q for Q3 2024. All systems go.

AI Summary

Oramed Pharmaceuticals Inc. filed its quarterly report for the period ending September 30, 2024. The company, incorporated in Delaware, is based in New York and operates in the pharmaceutical preparations sector. Its principal executive offices are located at 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036, with a contact phone number of 844-967-2633.

Why It Matters

This filing provides investors with the latest financial and operational updates for Oramed Pharmaceuticals, crucial for understanding the company's performance and future prospects.

Risk Assessment

Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or significant new risks disclosed.

Key Players & Entities

• ORAMED PHARMACEUTICALS INC. (company) — Registrant
• September 30, 2024 (date) — Quarterly period end date
• 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036 (location) — Principal Executive Offices
• 844-967-2633 (phone_number) — Registrant's Telephone Number
• Delaware (location) — State of Incorporation

FAQ

Key Financial Figures

• $0.012 — ich registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, Tel Avi
• $1.00 — by the Bank of Israel, was NIS 3.710 to $1.00. Unless indicated otherwise by the cont
• $1 — 0 * Represents an amount of less than $1. 4 ORAMED PHARMACEUTICALS INC. INT

Filing Documents

• ea0219486-10q_oramed.htm (10-Q) — 756KB
• ea021948601ex31-1_oramed.htm (EX-31.1) — 9KB
• ea021948601ex31-2_oramed.htm (EX-31.2) — 9KB
• ea021948601ex32-1_oramed.htm (EX-32.1) — 4KB
• ea021948601ex32-2_oramed.htm (EX-32.2) — 3KB
• 0001213900-24-095397.txt ( ) — 3961KB
• ormp-20240930.xsd (EX-101.SCH) — 34KB
• ormp-20240930_cal.xml (EX-101.CAL) — 36KB
• ormp-20240930_def.xml (EX-101.DEF) — 169KB
• ormp-20240930_lab.xml (EX-101.LAB) — 345KB
• ormp-20240930_pre.xml (EX-101.PRE) — 186KB
• ea0219486-10q_oramed_htm.xml (XML) — 479KB

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS: Balance sheets 2 of comprehensive income (loss) 3 of changes in stockholders' equity 4 of cash flows 6 Notes to financial statements 7 -18 1 ORAMED PHARMACEUTICALS INC. INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS U.S. Dollars in thousands (except share and per share data) (UNAUDITED) September 30, December 31, 2024 2023 Assets CURRENT ASSETS: Cash and cash equivalents $ 42,104 $ 9,055 Short-term deposits 42,741 95,279 Investments at fair value 57,455 57,713 Prepaid expenses and other current assets 474 537 Total current assets 142,774 162,584 LONG-TERM ASSETS: Long-term deposits 2 7 Investments at fair value 16,901 51,035 Marketable securities 646 1,807 Other non-marketable equity securities 3,524 3,524 Amounts funded in respect of employee rights upon retirement 30 27 Property and equipment, net 718 873 Operating lease right-of-use assets 486 694 Total long-term assets 22,307 57,967 Total assets $ 165,081 $ 220,551 Liabilities and stockholders' equity CURRENT LIABILITIES: Accounts payable and accrued expenses $ 4,995 $ 1,609 Short-term borrowings - 51,013 Payable to related parties 35 325 Operating lease liabilities 243 267 Total current liabilities 5,273 53,214 LONG-TERM LIABILITIES: Long-term deferred revenues 4,000 4,000 Employee rights upon retirement 29 28 Provision for uncertain tax position 11 11 Operating lease liabilities 186 342 Other liabilities 60 63 Total long-term liabilities 4,286 4,444 COMMITMENTS (note 5) EQUITY ATTRIBUTABLE TO COMPANY'S STOCKHOLDERS: Common stock, $ 0.012 par value ( 60,000,000 authorized shares; 40,209,575 and 40,338,979 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively) 484 485 Additional paid-in capital 322,384 320,892 Accumulated deficit ( 166,427 ) ( 157,556 ) Total s

View Full Filing

View this 10-Q filing on SEC EDGAR